Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Discontinuing PJP prophylaxis while on prednisone doses greater than 12.5 mg per day may elevate infection risk among patients with rheumatic diseases.

Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

The global burden of atopic dermatitis (AD) in older adults is considerable and is expected to continue increasing to 2050.

A low dose combination hormonal patch was found to be effective for pregnancy prevention based on results from a phase 3 study.

Use of a combined oral contraceptive (COC) is not associated with asthma in women of reproductive age, but use of a progestogen-only pill (POP) is associated with an increased risk for asthma attacks ...

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

Results of the updated systematic review informing the 2024 EULAR recommendations showed that many ARDs are safe to use during pregnancy, lactation, and reproduction.

Osteoboost, a targeted vibration therapy device, is now available to improve bone strength and bone density in postmenopausal women.